Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olaniyi Abideen Adigun has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advanced statistical approaches in tuberculosis diagnosis and treatment outcomes in Africa: a systematic review

    by Olalekan John Okesanya, Tolutope Adebimpe Oso, Blessing Olawunmi Amisu, Yakub Burhan Abdullahi, Mohamed Mustaf Ahmed, Uthman Okikiola Adebayo, Yusuf Hared Abdi, Christian Joseph N. Ong, Olaniyi Abideen Adigun, Jerico Bautista Ogaya, et al.

    Background: Tuberculosis (TB) remains a major public health challenge in Africa; however, conventional statistical approaches often fail to capture diagnostic uncertainty, spatial heterogeneity, and complex disease dynamics, limiting evidence-based decision-making. This review synthesizes the application and performance of advanced statistical and computational methods for TB diagnosis and treatment outcomes in Africa. Methods: Following the PRISMA 2020 guidelines, we systematically searched PubMed and Scopus for peer-reviewed studies (2010–2025) conducted in Africa that applied advanced methods, including Bayesian models, machine learning (ML) algorithms, spatiotemporal analyses, time-series models, and multistate or survival frameworks. Study selection, data extraction, and quality appraisal were independently conducted by multiple reviewers using the Joanna Briggs Institute tools. Findings were synthesized narratively because of substantial methodological heterogeneity. Results: Twenty-seven studies from nine African countries were included. Bayesian hierarchical, geostatistical, and latent class models improved estimation of TB incidence, mortality, and diagnostic accuracy by accounting for uncertainty, imperfect reference standards, and sparse data. Spatiotemporal analyses consistently identified geographic TB and TB–HIV hotspots linked to low Bacillus Calmette–Guérin vaccine coverage, illiteracy, and urban crowding as risk factors. Time-series models quantified the significant decline in TB notifications during the COVID-19 disruptions. ML approaches, particularly random forests, outperformed traditional regression in predicting latent TB infection and treatment outcomes. Drug resistance, notably to bedaquiline and levofloxacin, showed clear spatial clustering and dynamic progression patterns. Conclusions: Advanced statistical and computational methods are increasingly improving TB diagnosis, prognosis, and treatment insights in Africa by capturing complex patterns beyond classical models, but their broader impact is limited by data gaps, heterogeneity, and insufficient validation, highlighting the need for high-quality, multi-country research and stronger implementation frameworks. PROSPERO ID: CRD420251160248

  • Open Access

    Correction: Addressing the emerging threat of Oropouche virus: implications and public health responses for healthcare systems

    by Olalekan John Okesanya, Blessing Olawumi Amisu, Olaniyi Abideen Adigun, Mohamed Mustaf Ahmed, Abdulmajeed Opeyemi Agboola, Tolga Kab, Gilbert Eshun, Bonaventure Michael Ukoaka, Tolutope Adebimpe Oso, Jerico Bautista Ogaya, et al.


  • Top Cited Papers
    Open Access

    Building equitable and sustainable vaccine ecosystems in Africa to achieve health sovereignty and universal immunization by 2040

    by Olalekan John Okesanya, Mohamed Mustaf Ahmed, Zhinya Kawa Othman, Omar Abdulkarim Saeed Alhammadi, Adamu Muhammad Ibrahim, Olaniyi Abideen Adigun, Shuaibu Saidu Musa, Faiazul Haque Lamem, Edgar G. Cue, Don Eliseo-Lucero Prisno


  • Open Access

    Emerging technologies and innovative approaches to combat antimicrobial resistance: A narrative review of next-generation therapeutic strategies

    by Don Eliseo Lucero-Prisno, Olalekan John Okesanya, Abdulmajeed Opeyemi Agboola, Uthman Okikiola Adebayo, Olaniyi Abideen Adigun, Mohamed Mustaf Ahmed, Noah Olabode Olaleke, Tolutope Adebimpe Oso, Maria Ivy Rochelle S. Tan, Jerico Bautista Ogaya, et al.


  • Open Access

    Exploring immunotherapeutic strategies for bacterial and viral diseases

    by Ayodele Isaac Adedokun, Olaniyi Abideen Adigun, Adamu Muhammad Ibrahim, Ibrahim Idris, Paul Yiran Ntasin, Babatunde Ibrahim Olowu, Chinyere M. Ikele-Awaogu, Precious Kehinde Fadele, Ernesto Oluwafemi Dibia, Olalekan John Okesanya, et al.

    The global socioeconomic and health impacts of microbial diseases cannot be overemphasized. The emergence of the coronavirus in 2019 and the ongoing threat of infectious diseases, such as HIV/AIDS, tuberculosis, and hepatitis, remind us of the impact these infections have on economic stability and global health. Gaps in the treatment of microbial infections and their contribution to increased mortality necessitate holistic and long-term solutions, as opposed to antibiotics, which were previously relied upon. Immunotherapy is becoming increasingly promising for the treatment of microbial infections. This study reviews recent advances in immunotherapeutic strategies, particularly cytokine-based therapies, adoptive cell therapy, monoclonal antibodies, and immune checkpoint inhibitors, for the control of antimicrobial resistance. New inventive approaches, such as chimeric antigen receptor T cell therapy and mucosal-associated invariant T cells, have been discussed in the context of bacterial and viral infections, highlighting promising results from clinical trials and addressing the challenges of toxicity, immune evasion, and therapy resistance that are inherent in these diseases. Future priorities include optimizing combination therapies and exploring new immunomodulatory targets to improve the effectiveness of these interventions in treating antimicrobial resistance and other infectious diseases.


  • Top Cited Papers
    Open Access

    Integrating Digital Health Innovations to Achieve Universal Health Coverage: Promoting Health Outcomes and Quality Through Global Public Health Equity

    by Mohamed Mustaf Ahmed, Olalekan John Okesanya, Noah Olabode Olaleke, Olaniyi Abideen Adigun, Uthman Okikiola Adebayo, Tolutope Adebimpe Oso, Gilbert Eshun, Don Eliseo Lucero-Prisno

    Digital health innovations are reshaping global healthcare systems by enhancing access, efficiency, and quality of care. Technologies such as artificial intelligence, telemedicine, mobile health applications, and big data analytics have been widely applied to support disease surveillance, enable remote care, and improve clinical decision making. This review critically identifies persistent implementation challenges that hinder the equitable adoption of digital health solutions, such as the digital divide, limited infrastructure, and weak data governance, particularly in low- and middle-income countries (LMICs). It aims to propose strategic pathways for integrating digital innovations to strengthen universal health coverage (UHC) and bridge health disparities in the region. By analyzing the best global practices and emerging innovations, this study contributes to the ongoing dialogue on leveraging digital health for inclusive, scalable, and sustainable healthcare delivery in underserved regions.


  • Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence

    by Rehab Emad Ashmawy, Olalekan John Okesanya, Bonaventure Michael Ukoaka, Faithful Miebaka Daniel, Sonsochukwu Godfrey Ezedigwe, Abdulmajeed Opeyemi Agboola, Mohamed Mustaf Ahmed, Jerico Bautista Ogaya, Blessing Olawunmi Amisu, Olaniyi Abideen Adigun, et al.

    Background: Alzheimer's disease (AD) is a growing neurodegenerative disorder causing cognitive decline, memory loss, and functional impairment. Lecanemab has shown safety and efficacy in clinical trials. Objective: This review aims to understand the clinical evidence of lecanemab's effectiveness and safety in managing early AD. Methods: A systematic search was conducted using the Scopus database and ClinicalTrials.gov. Studies from 2014 to 2024 on lecanemab's safety, efficacy, and clinical outcomes for AD were included. Data extraction involved two independent reviewers, with synthesis using qualitative methodology. Results: Findings from 13 studies and 13 ongoing clinical trials were reported, showing that lecanemab substantially reduces amyloid plaque load in the brains of AD patients. The therapeutic regimens vary across reported studies and trials, ranging from 2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg monthly, and 10 mg/kg intravenously biweekly. The Clarity AD phase 3 trial, the AHEAD study, and the DIAN-TU-001 trials have reported positive study outcomes with robust efficacy and safety outcomes with minimal side effects. Completed and ongoing trials report on the onset of amyloid-related imaging abnormalities (ARIA) and the continuation of care status following the onset of ARIA in these patients. The common infusion-related reactions were observed in 26.4% of the lecanemab group compared to 7% in the placebo group. Conclusions: The management of AD has evolved over the years with the introduction of novel therapeutic agents like lecanemab. While its safety profile is generally favorable, careful monitoring is essential.


  • Top Cited Papers
    Open Access

    A comprehensive review of mental health services across selected countries in sub-Saharan Africa: assessing progress, challenges, and future direction

    by Faith Atewologun, Olaniyi Abideen Adigun, Olalekan John Okesanya, Hakeem Kayode Hassan, Olaleke Noah Olabode, Abioye Sunday Micheal, Mohamed Mustaf Ahmed, Bonaventure Michael Ukoaka, Nimat Bola Idris, Tolutope Adebimpe Oso, et al.

    Mental health is a crucial but frequently neglected aspect of general health and well-being that faces numerous challenges, including underfunding, shortage of trained professionals, pervasive stigma, inadequate infrastructure, and insufficient policies in sub-Saharan Africa. This review reports the significant progress and initiatives that have been made in this region. South Africa, Nigeria, Uganda, Kenya, Tanzania, Ethiopia, Rwanda, and Ghana have developed national policies and integrated mental health services into primary healthcare, marking a shift towards community-based care and reducing stigma through awareness campaigns. Countries such as South Africa and Rwanda have robust infrastructure, while Ethiopia and Kenya emphasize training primary healthcare providers and community-based models. Ghana’s Mental Health Act and Uganda’s collaboration with NGOs has enhanced awareness and resource mobilization. Mental healthcare-targeted programs, such as Kenya’s Friendship Bench and Ethiopia’s Health Extension Program, have demonstrated the efficacy of community-based interventions. South Africa has leveraged innovative approaches, such as telepsychiatry, to expand access to holistic mental health services, particularly in rural areas. Partnerships with traditional healers in Uganda and Rwanda have enhanced early identification and referral. Despite these advancements, challenges persist. Common issues include a severe shortage of mental health professionals, inadequate budget allocation, limited access to services in rural areas, and the need for comprehensive policy frameworks that continue to stall the desired goals. Urban-centric services in Nigeria, financial constraints in Tanzania, and resource limitations in Ethiopia and Rwanda have hindered equitable access. While public–private partnerships and technological innovations are emerging, the dominance of institutionalized care in several regions limits community outreach. To chart the path forward, improving mental health services in Sub-Saharan Africa requires increased funding, expanded training programs for mental health professionals, and incorporation of mental health into basic healthcare systems. Utilizing technology such as telemedicine and mobile health applications holds promise for overcoming geographical barriers and supporting ongoing education. Community-based models and advocacy efforts are essential for reducing stigma, promoting sustainable mental healthcare, and enhancing the overall well-being of citizens insub-Saharan Africa.


  • Top Cited Papers
    Open Access

    Reinvigorating AMR resilience: leveraging CRISPR–Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security—a systematic review

    by Olalekan John Okesanya, Mohamed Mustaf Ahmed, Jerico Bautista Ogaya, Blessing Olawunmi Amisu, Bonaventure Michael Ukoaka, Olaniyi Abideen Adigun, Emery Manirambona, Olakulehin Adebusuyi, Zhinya Kawa Othman, Olanegan Gloria Oluwakemi, et al.

    Background: Antimicrobial resistance (AMR) poses a global health threat, particularly in low- and middle-income countries (LMICs). Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas system technology offers a promising tool to combat AMR by targeting and disabling resistance genes in WHO bacterial priority pathogens. Thus, we systematically reviewed the potential of CRISPR–Cas technology to address AMR. Methods: This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted using the Scopus and PubMed databases, focusing on publications from 2014 to June 2024. Keywords included “CRISPR/Cas,” “antimicrobial resistance,” and “pathogen.” The eligibility criteria required original studies involving CRISPR/Cas systems that targeted AMR. Data were extracted from eligible studies, qualitatively synthesized, and assessed for bias using the Joanna Briggs Institute (JBI)-standardized tool. Results: Data from 48 eligible studies revealed diverse CRISPR–Cas systems, including CRISPR–Cas9, CRISPR–Cas12a, and CRISPR–Cas3, targeting various AMR genes, such as blaOXA-232, blaNDM, blaCTX-M, ermB, vanA, mecA, fosA3, blaKPC, and mcr-1, which are responsible for carbapenem, cephalosporin, methicillin, macrolide, vancomycin, colistin, and fosfomycin resistance. Some studies have explored the role of CRISPR in virulence gene suppression, including enterotoxin genes, tsst1, and iutA in Staphylococcus aureus and Klebsiella pneumoniae. Delivery mechanisms include bacteriophages, nanoparticles, electro-transformation, and conjugative plasmids, which demonstrate high efficiency in vitro and in vivo. CRISPR-based diagnostic applications have demonstrated high sensitivity and specificity, with detection limits as low as 2.7 × 102 CFU/mL, significantly outperforming conventional methods. Experimental studies have reported significant reductions in resistant bacterial populations and complete suppression of the targeted strains. Engineered phagemid particles and plasmid-curing systems have been shown to eliminate IncF plasmids, cured plasmids carrying vanA, mcr-1, and blaNDM with 94% efficiency, and restore antibiotic susceptibility. Gene re-sensitization strategies have been used to restore fosfomycin susceptibility in E. coli and eliminate blaKPC-2-mediated carbapenem resistance in MDR bacteria. Whole-genome sequencing and bioinformatics tools have provided deeper insights into CRISPR-mediated defense mechanisms. Optimization strategies have significantly enhanced gene-editing efficiencies, offering a promising approach for tackling AMR in high-priority WHO pathogens. Conclusions: CRISPR–Cas technology has the potential to address AMR across priority WHO pathogens. While promising, challenges in optimizing in vivo delivery, mitigating potential resistance, and navigating ethical-regulatory barriers must be addressed to facilitate clinical translation.


  • Top Cited Papers
    Open Access

    Holistic Approaches to Zoonoses: Integrating Public Health, Policy, and One Health in a Dynamic Global Context

    by Mohamed Mustaf Ahmed, Olalekan John Okesanya, Zhinya Kawa Othman, Adamu Muhammad Ibrahim, Olaniyi Abideen Adigun, Bonaventure Michael Ukoaka, Muhiadin Ismail Abdi, Don Eliseo Lucero-Prisno

    Zoonotic diseases pose a significant global health threat, driven by factors such as globalization, climate change, urbanization, antimicrobial resistance (AMR), and intensified human–animal interactions. The increasing interconnectedness of human, animal, and environmental health underscores the importance of the OH paradigm in addressing zoonotic threats in a globalized world. This review explores the complex epidemiology of zoonotic diseases, the challenges associated with their management, and the necessity for cross-sector collaboration to enhance prevention and control efforts. Key public health strategies, including surveillance systems, infection control measures, and community education programs, play crucial roles in mitigating outbreaks. However, gaps in governance, resource allocation, and interdisciplinary cooperation hinder effective disease management, particularly in low- and middle-income countries (LMICs). To illustrate the effectiveness of the OH approach, this review highlights successful programs, such as the PREDICT project, Rwanda’s National One Health Program, the EcoHealth Alliance, and the Rabies Elimination Program in the Philippines. These initiatives demonstrate how integrating human, animal, and environmental health efforts can enhance early detection, improve outbreak responses, and reduce public health burdens. Strengthening global health governance, enhancing surveillance infrastructure, regulating antimicrobial use, and investing in research and technological innovations are essential steps toward mitigating zoonotic risks. Ultimately, a coordinated, multidisciplinary approach is vital for addressing the dynamic challenges posed by zoonotic diseases and ensuring global health security in an increasingly interconnected world.